GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
New Data Add To Confidence
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
You may also be interested in...
New Phase III pancreatic cancer results for GV1001, an immunotherapeutic peptide, were presented at ASCO, which GemVax hopes will revive the drug after its conditional approval in South Korea was canceled last year.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.